fda compounding semaglutide enforcement 2025 news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our The FDA says it plans

Connect with a weight loss healthcare provider through Klinic to receive a prescription

These large-scale studies will clarify long-term safety, cardiovascular outcomes, and real-world durability of benefit

I vowed never to let my weight affect my career

Get in Touch Questions

For tirzepatide, the average weight loss is 8.31 pounds in the first month, (not even a pound greater than semaglutide), 15.73 pounds over the first two months (almost three pounds more than semaglutide), 19.34 pounds over the first three months (a pound greater than semaglutide) and 26.40 pounds over the first four months (three pounds more than semaglutide)

UK patients rely on Cloud